Risk of hepatitis B reactivation in patients treated with direct-acting antivirals for hepatitis C

Table 1 Overview of clinical characteristics in patients with hepatitis C virus/hepatitis B virus coinfection who had hepatitis B virus reactivation during direct-acting antiviral drugs - based hepatitis C virus treatment

Patients’ characteristics					HCV Treatment		HBV Infection
Ref	Gender	Age	HIV coinfection	HCV genotype	Previous treatment	DAA regimen	Profile before DAAs1	HBV DNA (IU/mL) before/after DAAs2	ALT levels (IU/L) before/after DAAs3	Week4
Collins et al[21]	M	55	No	1a	IFN/ribavirin	Sofosbuvir/simeprevir	Inactive carrier	2.300/ 22 million	62/1.495	8
Collins et al[21]	M	57	No	1a	IFN/ribavirin	Sofosbuvir/simeprevir	Occult infection	20/11.255	Within normal limits	4
Ende et al[20]	F	59	No	1b	IFN/ribavirin	Sofosbuvir/simeprevir/ ribavirin	Resolved infection	Undetectable/ 29 million	168/2.263	11
Takayama et al[17]	M	69	No	1b	No treatment	Daclatasvir/asunaprevir	Inactive carrier	310/10 million	94/237	6
De Monte et al[19]	M	53	Yes	4d	IFN/ribavirin	Sofosbuvir/ledipasvir	Resolved infection	Undetectable/ 960 million	Within normal limits /1.026	6
Hayashi et al[18]	F	83	No	1b	No treatment	Daclatasvir/asunaprevir	Unclear	Undetectable/ 1.000.000	Within normal limits/1.066	48
Madonia et al[22]	F	62	No	2	No treatment	Sofosbuvir/ribavirin	Resolved infection	Undetectable/ 2.080.000	34/1.896	36

¹Profile of HBV infection according to HBV viral load and HBs antigen detection;

²HBV viral load before DAA treatment and at initiation of HBV reactivation;

³ALT levels before DAA treatment and at initiation of HBV reactivation;

⁴Weeks after the initiation of DAA treatment. HIV: Human immunodeficiency virus; HCV: Hepatitis C virus; HBV: Hepatitis B virus; IFN: Pegylated interferon; ALT: Alanine transaminase; DAA: Direct-acting antiviral drugs.